Turner, Jackson S.
O’Halloran, Jane A. http://orcid.org/0000-0001-8265-9471
Kalaidina, Elizaveta
Kim, Wooseob http://orcid.org/0000-0002-9199-1000
Schmitz, Aaron J. http://orcid.org/0000-0002-8077-6751
Zhou, Julian Q. http://orcid.org/0000-0001-9602-2092
Lei, Tingting
Thapa, Mahima
Chen, Rita E.
Case, James Brett http://orcid.org/0000-0001-7331-5511
Amanat, Fatima http://orcid.org/0000-0002-8029-8227
Rauseo, Adriana M.
Haile, Alem
Xie, Xuping http://orcid.org/0000-0003-0918-016X
Klebert, Michael K.
Suessen, Teresa
Middleton, William D.
Shi, Pei-Yong http://orcid.org/0000-0001-5553-1616
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Teefey, Sharlene A.
Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
Presti, Rachel M. http://orcid.org/0000-0002-5469-0727
Ellebedy, Ali H. http://orcid.org/0000-0002-6129-2532
Article History
Received: 8 March 2021
Accepted: 18 June 2021
First Online: 28 June 2021
Competing interests
: The laboratory of A.H.E. received funding under sponsored research agreements that are unrelated to the data presented in the current study from Emergent BioSolutions and from AbbVie. A.H.E. is a consultant for Mubadala Investment Company and the founder of ImmuneBio Consulting. J.S.T., A.J.S., M.S.D. and A.H.E. are recipients of a licensing agreement with Abbvie that is unrelated to the data presented in the current study. M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The laboratory of M.S.D. has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology and Emergent BioSolutions. A patent application related to this work has been filed by Washington University School of Medicine. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The laboratory of F.K. is also collaborating with Pfizer on animal models of SARS-CoV-2. The laboratory of P.-Y.S. has received sponsored research agreements from Pfizer, Gilead, Merck and IGM Sciences Inc. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official view of NIAID or NIH.
Free to read: This content has been made available to all.